Latest Regulatory Milestones News

Battery Minerals Ltd has launched comprehensive geophysical and geochemical programs at its El Aguila Gold-Silver Project in Argentina, setting the stage for maiden drilling in Q3 2025 pending approvals.

Predictive Discovery Limited has reported robust drilling results at its Bankan Gold Project in Guinea, alongside key environmental approvals and a strategic A$69 million capital raise, positioning the company for accelerated development.

Titanium Sands Limited has secured the Terms of Reference for the Environmental Impact Assessment of its Mannar Heavy Mineral Project, marking a pivotal regulatory milestone. The company is also progressing tenure retention applications amid plans for further capital raising.

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

European Metals Holdings has achieved key regulatory milestones for its Cinovec Lithium Project, including EU Strategic Project status and a $36 million grant, positioning it as a pivotal supplier in Europe’s lithium supply chain.

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

Pantera Lithium has identified six high-priority drilling locations for its Smackover Lithium Brine Project, supported by promising Arkansas legislation offering fiscal and regulatory incentives that could reshape the project's economics.

NuEnergy Gas Limited has initiated drilling site preparation at its Tanjung Enim PSC, progressing towards early gas sales, while securing key commercial agreements and maintaining a strong cash position.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.

Lumos Diagnostics reported a 21% quarter-on-quarter revenue increase in Q3 FY25, driven by strong product sales and expanded development agreements. The company also secured Medicare coverage in key US regions and advanced its pivotal FebriDx CLIA waiver study with FDA submission expected by year-end.